A detailed history of China Universal Asset Management Co., Ltd. transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 16,249 shares of IDYA stock, worth $451,234. This represents 0.06% of its overall portfolio holdings.

Number of Shares
16,249
Previous 8,893 82.72%
Holding current value
$451,234
Previous $312,000 64.74%
% of portfolio
0.06%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$30.37 - $43.05 $223,401 - $316,675
7,356 Added 82.72%
16,249 $514,000
Q2 2024

Jul 19, 2024

SELL
$34.37 - $43.46 $187,453 - $237,030
-5,454 Reduced 38.01%
8,893 $312,000
Q1 2024

Apr 29, 2024

BUY
$34.2 - $47.13 $235,774 - $324,914
6,894 Added 92.5%
14,347 $630,000
Q4 2023

May 21, 2024

SELL
$24.59 - $35.83 $169,523 - $247,012
-6,894 Reduced 48.05%
7,453 $265,000
Q4 2023

Jan 23, 2024

BUY
$24.59 - $35.83 $147,023 - $214,227
5,979 Added 405.63%
7,453 $265,000
Q3 2023

May 21, 2024

BUY
$21.07 - $29.77 $15,233 - $21,523
723 Added 96.27%
1,474 $39,000
Q3 2023

Oct 30, 2023

BUY
$21.07 - $29.77 $15,233 - $21,523
723 Added 96.27%
1,474 $40,000
Q2 2023

May 21, 2024

BUY
$13.33 - $25.53 $1,319 - $2,527
99 Added 15.18%
751 $17,000
Q2 2023

Jul 27, 2023

BUY
$13.33 - $25.53 $1,319 - $2,527
99 Added 15.18%
751 $18,000
Q1 2023

May 21, 2024

BUY
$13.49 - $18.72 $2,198 - $3,051
163 Added 33.33%
652 $8,000
Q1 2023

Apr 27, 2023

BUY
$13.49 - $18.72 $2,198 - $3,051
163 Added 33.33%
652 $9,000
Q4 2022

May 21, 2024

SELL
$14.47 - $18.17 $200,525 - $251,799
-13,858 Reduced 96.59%
489 $8,000
Q4 2022

Jan 31, 2023

BUY
$14.47 - $18.17 $1,750 - $2,198
121 Added 32.88%
489 $9,000
Q3 2022

Oct 21, 2022

BUY
$9.24 - $15.79 $3,400 - $5,810
368 New
368 $5,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.33B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.